Get the Stockscreener App
3.95
178.17%
2.53
After Hours:
3.94
-0.01
-0.25%
Inozyme Pharma Inc stock is traded at $3.95, with a volume of 49.78M.
It is up +178.17% in the last 24 hours and up +310.69% over the past month.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
See More
Previous Close:
$1.42
Open:
$3.95
24h Volume:
49.78M
Relative Volume:
32.46
Market Cap:
$255.01M
Revenue:
-
Net Income/Loss:
$-71.17M
P/E Ratio:
-2.8417
EPS:
-1.39
Net Cash Flow:
$-70.97M
1W Performance:
+243.48%
1M Performance:
+310.69%
6M Performance:
+26.40%
1Y Performance:
-16.49%
1-Day Range:
$3.94
$3.96
1-Week Range:
$1.05
$3.96
52-Week Range:
$0.721
$6.24
Inozyme Pharma Inc Stock (INZY) Company Profile
Name
Inozyme Pharma Inc
Sector
Industry
Phone
857-330-4340
Address
321 SUMMER STREET, BOSTON
Compare INZY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
3.95 | 74.25M | 0 | -71.17M | -70.97M | -1.39 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Raymond James | Outperform |
| Sep-12-24 | Initiated | Stifel | Buy |
| Aug-13-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| Mar-23-23 | Upgrade | Jefferies | Hold → Buy |
| May-26-22 | Initiated | Jefferies | Hold |
| Feb-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-29-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Inozyme Pharma Inc Stock (INZY) Latest News
Inozyme downgraded to Hold from Buy at TD Cowen - TipRanks
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock New - GuruFocus
BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 By Investing.com - Investing.com South Africa
TD Cowen cuts Inozyme stock rating post-acquisition news By Investing.com - Investing.com Nigeria
Inozyme (INZY) Downgraded Following Acquisition Deal | INZY Stock News - GuruFocus
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech
BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News
Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by J - GuruFocus
Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by Jefferies | INZY Stock News - GuruFocus
Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment - TipRanks
Inozyme (INZY) Downgraded Following Acquisition by BioMarin | INZY Stock News - GuruFocus
Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily
BioMarin stock rises following Inozyme Pharma acquisition - Investing.com
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M - TipRanks
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 - Investing.com India
Jefferies Downgrades Inozyme Pharma to Neutral From Buy - marketscreener.com
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges - TipRanks
Jefferies Downgrades Inozyme (INZY) After Acquisition Announceme - GuruFocus
Inozyme downgraded to Hold from Buy at Jefferies - TipRanks
Cooley, Goodwin Build BioMarin's $270M Inozyme Buy - Law360
BioMarin grows enzyme portfolio with $270M Inozyme buy - FirstWord Pharma
BioMarin (BMRN) Set to Acquire Inozyme Pharma for $270M | BMRN Stock News - GuruFocus
Leerink bullish on BioMarin following Inozyme deal, expects additional BD - TipRanks
Inozyme Pharma (INZY) Downgraded by Needham Analyst | INZY Stock News - GuruFocus
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - Asianet Newsable
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc.INZY - PR Newswire
Inozyme (INZY) Downgraded Following Acquisition Agreement | INZY Stock News - GuruFocus
BioMarin to buy rare disease drugmaker Inozyme for $270M - BioPharma Dive
BioMarin Pharmaceutical Inc. agreed to acquire Inozyme Pharma, Inc.. - marketscreener.com
Inozyme downgraded to Hold from Buy at Needham - TipRanks
Inozyme (INZY) Downgraded by Wells Fargo Following Acquisition N - GuruFocus
Wells Fargo Downgrades Inozyme Pharma to Equal Weight From Overweight, $4 Price Target - marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders - marketscreener.com
Inozyme downgraded to Equal Weight from Overweight at Wells Fargo - TipRanks
Inozyme Pharma, Emerson Electric, Stanley Black & Decker - TradingView
Inozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential - TipRanks
BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme - Endpoints News
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover - MSN
BioMarin expands enzyme expertise with $270M Inozyme buy - PharmaLive
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Inozyme Pharma, Inc. (INZY) - TradingView
Inozyme (INZY) Downgraded After BioMarin Acquisition Announcement | INZY Stock News - GuruFocus
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders - Bluefield Daily Telegraph
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy - BioSpace
Wedbush Downgrades Inozyme Pharma to Neutral From Outperform, Adjusts Price Target to $4 From $7 - marketscreener.com
BioMarin to Acquire Inozyme Pharma for $270M - Contract Pharma
BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com Canada
BioMarin Acquires Inozyme Pharma for $270 Million - TipRanks
BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era - Fierce Biotech
Inozyme Pharma Merges with BioMarin for $270 Million - TipRanks
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
Inozyme Pharma Inc Stock (INZY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):